Spectral AI (NASDAQ: MDAI) has affirmed its sales guidance for FY2026 at $18.500 million, confirming its previous outlook despite a slight miss against the $18.538 million market estimate. The company’s decision to maintain its target suggests management confidence in its operational trajectory, even as it falls just short of external analyst expectations.

The reaffirmed guidance of $18.500 million remains consistent with the company’s earlier projections, signaling no change in strategic direction or revenue assumptions for the fiscal year. This stability is notable given the narrow variance between the guided amount and the estimated $18.538 million, which represents a difference of less than 0.2%.

Guidance Details

The alignment between the updated and previous guidance figures underscores a disciplined approach to revenue forecasting. Investors should note that while the guidance is unchanged, the slight underperformance relative to estimates may reflect conservative positioning in a competitive market environment.

What the Numbers Show

The minimal gap between Spectral AI’s guided sales of $18.500 million and the estimate of $18.538 million indicates that market expectations were closely calibrated to the company’s own projections. This narrow divergence suggests that analysts had limited room for upward revision, potentially due to visibility constraints in the sector or recent macroeconomic factors affecting demand forecasts.

Spectral AI, Inc. (NASDAQ: MDAI) reported second-quarter earnings per share (EPS) of $(0.13), beating the analyst consensus estimate of $(0.14). However, the Dallas-based medical diagnostics company’s quarterly sales of $3.524 million missed the $4.145 million estimate by 14.98 percent. The results reflect a 58.06 percent improvement in losses compared to $(0.31) per share in the same period last year, while revenue declined 30.42 percent from $5.065 million in Q2 2025.

The beat on EPS was driven primarily by non-operational factors rather than core business performance. Spectral AI attributes its improved bottom line to a $0.7 million non-cash benefit from changes in the fair value of its warrant liability. This gain offset operational headwinds, including a compression in gross margin to 31.6% from 45.2% year-over-year. The margin contraction stems from cost-share provisions in the follow-on development phase of the company’s Project BioShield contract with the Biomedical Advanced Research and Development Authority (BARDA).

Revenue decline aligns with anticipated decreases in reimbursed costs under the BARDA contract as the scope of work narrowed following FDA clearance. Additionally, revenue from other U.S. government contracts fell as Spectral AI completed performance obligations under its Department of Defense contract via the Medical Technology Enterprise Consortium (MTEC). Despite the miss on sales estimates, the company secured a pivotal operational milestone: the U.S. Food and Drug Administration (FDA) granted De Novo clearance for Spectral AI’s DeepView System for burn indication in May 2026.

Operating expenses rose 23.2% to $5.4 million from $4.4 million in Q2 2025, reflecting the company’s transition toward commercial activities. General and administrative expenses increased by $0.5 million due to equity awards, while selling and marketing activities grew by $0.3 million ahead of first commercial sales. The balance sheet remains fortified with $14.0 million in cash as of June 30, 2026, supported by a $6.5 million draw under an existing credit facility with Avenue Capital Group.

Key Financial Metrics vs Estimates

What the Numbers Show

The divergence between the EPS beat and the revenue miss highlights the significant impact of financing-related accounting items on Spectral AI’s results. While the core business faced headwinds—with gross margin contracting and operating expenses rising—the reported net loss was substantially mitigated by the warrant liability gain. In the prior year’s comparable period, this line item represented a $5.4 million expense. This volatility underscores that the improvement in net loss is not yet reflective of operational profitability but rather of favorable market-driven adjustments to derivative liabilities.